Article
Endocrinology & Metabolism
Catherine Y. Zhu, Hui X. Zhou, Chi-Hong Tseng, Oliver J. Fackelmayer, Philip Haigh, Annette L. Adams, Michael W. Yeh
Summary: This study investigated the natural progression of kidney function in patients with primary hyperparathyroidism (PHPT) and whether parathyroidectomy has an effect on renal outcomes. The results showed that PHPT patients had an accelerated decline in kidney function compared to matched controls, and among patients with hypercalcemia, parathyroidectomy was associated with decreased decline in kidney function.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Enrique Soto-Pedre, Paul J. Newey, Sundararajan Srinivasan, Moneeza K. Siddiqui, Colin N. A. Palmer, Graham P. Leese
Summary: This study investigates the genetic associations with primary hyperparathyroidism (PHPT) using both a genome-wide association study (GWAS) and candidate gene approaches. The results suggest that genetic variants at SOX9, SLITRK5, LPAR3, and BCDIN3D-AS1 are associated with an increased risk of PHPT. Furthermore, carriers of more PHPT-risk alleles, both male and female, have a significantly higher risk of developing PHPT.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Surgery
T. Weber, C. Dotzenrath, H. Dralle, B. Niederle, P. Riss, K. Holzer, J. Kussmann, A. Trupka, T. Negele, R. Kaderli, E. Karakas, F. Weber, N. Rayes, A. Zielke, M. Hermann, C. Wicke, R. Ladurner, C. Vorlaender, J. Waldmann, O. Heizmann, S. Waechter, S. Schopf, W. Timmermann, D. K. Bartsch, R. Schmidmaier, M. Luster, K. W. Schmid, M. Ketteler, C. Dierks, P. Schabram, T. Steinmueller, K. Lorenz
Summary: This review provides updated recommendations for the surgical management of primary and renal hyperparathyroidism. Surgery remains the only curative treatment for pHPT, while a more selective approach is required for rHPT.
LANGENBECKS ARCHIVES OF SURGERY
(2021)
Review
Medicine, Research & Experimental
Mykayla L. Sandler, Rebecca Ho, Monica H. Xing, Sunder Gidumal, Hannah Spitzer, Juliana C. Levy, Raymond L. Chai
Summary: The study indicates that parathyroidectomy should be considered for all pregnant patients with diagnosed hyperparathyroidism, regardless of symptomatology. Surgery poses fewer risks than conservative treatments and leads to better fetal outcomes. Surgery in the third trimester is feasible and should be considered for both symptomatic and asymptomatic patients.
Article
Endocrinology & Metabolism
Carolyn D. Seib, Calyani Ganesan, Katherine D. Arnow, Alan C. Pao, John T. Leppert, Nicolas B. Barreto, Electron Kebebew, Manjula Kurella Tamura
Summary: A longitudinal cohort study found that patients with primary hyperparathyroidism (PHPT) who underwent parathyroidectomy were at a higher risk of kidney stone events in the immediate years after treatment compared to those managed nonoperatively, although the adjusted risk declined over time.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Izabela Karwacka, Piotr Kmiec, Sonia Kaniuka-Jakubowska, Izabela Pisowodzka, Marcin Fijalkowski, Krzysztof Sworczak
Summary: Cardiovascular mortality is higher in patients with primary hyperparathyroidism (PHPT) compared to the general population. The role of the renin-angiotensin-aldosterone system (RAAS) in cardiovascular pathology in PHPT is unclear, as is the effect of successful parathyroidectomy (PTX) on hypertension and left-ventricular dysfunction.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Cristian Iorga, Cristina Raluca Iorga, Iuliana Andreiana, Iustinian Bengulescu, Traian Constantin, Victor Strambu
Summary: After analyzing the obtained results, it was concluded that total parathyroidectomy is the preferred intervention for patients with secondary hyperparathyroidism when pharmacotherapy fails, in order to prevent disease recurrence and correct metabolic parameters.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Surgery
Alaa Sada, Kristine T. Hanson, Elizabeth B. Habermann, Travis J. McKenzie, Melanie L. Lyden, Trenton R. Foster, Bart L. Clarke, Benzon M. Dy
Summary: This study evaluated the underperformance of parathyroidectomy in patients with primary hyperparathyroidism and explored barriers to care. It was found that insurance type was associated with undergoing surgery, with patients on governmental insurance less likely to undergo surgery and waiting longer for surgery. Barriers to referral and access to surgery should be investigated and addressed to optimize patients' access to care.
JOURNAL OF SURGICAL RESEARCH
(2023)
Review
Medicine, General & Internal
Mara Carsote, Claudiu Nistor
Summary: Hungry bone syndrome (HBS) is a severe hypocalcemia that occurs after parathyroidectomy (PTX), resulting from the rapid drop in PTH (parathormone) levels. It is commonly seen in primary hyperparathyroidism (PHPT) or renal hyperparathyroidism (RHPT) patients and can have negative effects on the outcome of parathyroid disease.
Article
Surgery
Samuel Frey, Bastien Perrot, Cecile Caillard, Maelle Le Bras, Maxime Gerard, Claire Blanchard, Bertrand Cariou, Matthieu Wargny, Eric Mirallie
Summary: This study evaluated the long-term impact of parathyroidectomy (PTX) on quality of life (QoL) in patients with primary hyperparathyroidism (PHPT). The results showed that QoL significantly improved at 1 year and was sustained for at least 3 years after PTX. Additionally, while the physical component score normalized after 3 years, the mental component score remained lower than the reference population.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Endocrinology & Metabolism
Robert A. Wermers, Marcio L. Griebeler, Prabin Thapa, Matthew A. Hathcock, Ann E. Kearns
Summary: Overall, the survival of patients with primary hyperparathyroidism (PHPT) in a community population in the United States was not significantly different from that of white Minnesota residents. However, individuals with a maximum serum calcium level > 10.8 mg/dL had an increased risk of mortality. Survival was improved after parathyroidectomy in patients with serum calcium levels >10.8 mg/dL.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ying Wei, Zhen-Long Zhao, Xiao-Jing Cao, Li-Li Peng, Yan Li, Jie Wu, Ming-An Yu
Summary: This study compared the clinical outcomes of microwave ablation (MWA) and parathyroidectomy (PTX) for the treatment of primary hyperparathyroidism (pHPT) and found no significant differences in cure rate, persistent and recurrent disease rates, or major complications between the two methods. MWA had the advantage of shorter procedure time and smaller incision length, but slightly higher costs.
EUROPEAN RADIOLOGY
(2022)
Review
Oncology
Katherine A. Cironi, Peter P. Issa, Aaron L. Albuck, Christina McCarthy, Leely Rezvani, Mohammad Hussein, Xinyi Luo, Mohamed Shama, Eman Toraih, Emad Kandil
Summary: Patients undergoing medical treatment for mild pHPT have higher calcium and PTH levels. Comparing the outcomes of medical management and parathyroidectomy, it is found that parathyroidectomy has superior results in biochemical and musculoskeletal aspects. Therefore, parathyroidectomy should be considered a better treatment option for most patients with mild pHPT.
Review
Endocrinology & Metabolism
Muizz Zaman, Laxshika Raveendran, Ayla Senay, Harlan Sayles, Runa Acharya, Mashaal Dhir
Summary: This study conducted a systematic review and meta-analysis to investigate the long-term recurrence rates of sporadic PHPT after successful parathyroidectomy. The results showed that approximately 1.56% of patients with sporadic PHPT developed recurrence following surgery. The initial diagnosis and procedure type did not have a significant impact on recurrence rates, emphasizing the importance of consistent long-term follow-up.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Medicine, Research & Experimental
Imran M. Khawaja, Avneet Randhawa, Karandeep Randhawa, Owais M. Aftab, Roshan V. Patel, Jean Anderson Eloy, Christina H. Fang
Summary: This study identifies an association between hypoalbuminemia and adverse outcomes in patients undergoing parathyroidectomy for primary hyperparathyroidism.